Posts for Ticker ‘ANPI’

Top Day Trader Alerts (CIT, ANDS, AVNR, BG, ANPI, RINO)

These are this morning’s top day trader alert and actively traded stocks.  We have links through to each with more detailed price and volume data and analysis over at VSInvestor.com:

CIT Group, Inc. (NYSE: CIT) is down over 20% after it delayed its 10-Q filing amid restructuring.  Worse talk is out there…

Anadys Pharma (NASDAQ: ANDS) is up 30% or more on early clinical trial in Hepatitis C patient data.

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) is hitting 52-week highs after showing positive Phase III study results for Zenvia.

Bunge Limited (NYSE: BG) is down 4% on a surprise secondary offering.

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI) is up over 30% as a license holder reported a CE Mark approval.

RINO International Corporation (NASDAQ: RINO) was very active last night after earnings and is down 17% this morning.

JON C. OGG
AUGUST 11, 2009

Posted on: August 11, 2009 – 8:57 am in Pre-Market Activity, Trading Alert, , , , , ,

Drug-Eluting Stent Data Shows More Promise (BSX, ANPI, JNJ, SRDX, MDT, ABT)

Stent_imageThe Massachusetts Department of Public Health funded a study which is showing further evidence to support the use of drug eluting stents over bare metal stents in heart attack patients.  This study measured stent use in diabetic patients. 

While the study did not show which exact stents were under comparison, it does at least give some timeframes.  The larger historic drug-eluting stents and their makers are Taxus by Boston Scientific (NYSE: BSX) with Angiotech (NASDAQ: ANPI) as the molecule maker for Taxus, and  Cypher by Johnson & Johnson (NYSE: JNJ) with SurModics (SRDX) as the molecule maker for Cypher.

Read More »

Posted on: November 11, 2008 – 12:01 pm in Medical, , , , , ,

The 52-Week Low Club 9/23/2008 (OSK)(IGT)(GME)(ANPI)

Newspaper_2Oshkosh (OSK) Hit by class action suit over SEC disclosure regulations. Falls to $9.05 from 52-week high of $63.55.

International Game Technology (IGT) Concerns it will lose patent lawsuit. Drops to $15.22 from 52-week high of $49.41.

Gamestop (GME) Dips on concerns video game market is slowing. Sells off to $34.52 from 52-week high of $63.77.

Angiotech Pharmaceuticals (ANPI) Cuts staff and terminates tender offer. Plunges to $.53 from 52-week high of $7.90.

Douglas A. McIntyre

Posted on: September 23, 2008 – 2:43 pm in HI/LOW, , , ,

The 52-Week Low Club 9/22/2008 (RTI)(ANPI)(NTAP)

Sad_clownRTL Intl Metals (RTI) No news but drop in titanium demand due to Boeing (BA) strike could be culprit. Falls to $20.04 from 52-week high of $85.20.

Angiotech Pharmaceuticals (ANPI) Cutting costs and having trouble with financing. Drops to $.90 from 52-week high of $7.90.

NetApp (NTAP) Downgrade from Wachovia. Sells down to $18.70 from 52-week high of $32.38.

Douglas A. McIntyre

Posted on: September 22, 2008 – 2:49 pm in HI/LOW, , ,

This Week’s BioHealth & Biotech Top Stories

We saw another exciting week full of news for key developments in drug stocks, biotech stocks, medical device stocks, and other companies involved in various aspects of health care and medicine.  Below are some of the stock tickers we covered over at BioHealthInvestor.com this week:

  • STOCK TICKERS: ABT, BSX, MDT, JNJ, SRDX, ANPI, BAYRY, MAXY, AMGN, CRA, INGN, CELG, MRK, SNY, GSK, AKRX, ARYX

This week we saw another FDA Approval in stents as Abbott’s (NYSE: ABT) XIENCE drug-eluting coronary stent was approved for marketing.  While this is causing a resurgence in stents, this space is about to become highly competitive (stocks covered: ABT, BSX, MDT, JNJ, SRDX, ANPI).  Introgen (NASDAQ: INGN) has a new twist for head and neck cancer… give it a cold, literally.  Celgene Corp. (NASDAQ: CELG) actually won out as a competitor’s bone marrow disease trials failed to meet expectations.  Merck (NYSE: MRK) was an FDA decision winner as it gets to keep its lead on the cervical cancer vaccine market in the U.S. tied up for at least 6-months longer than it was anticipated (stocks covered: MRK, SNY, GSK).

This may be a tiny company, but a patent was awarded in bone marrow and stem cell transplants.  While a biotech turned over its hemophelia treatments to a larger company, hemophelia treatments may be better off now (stocks covered: BAYRY, MAXY, AMGN).  Vaccine awards are going to keep sales up at one small vaccine maker.  One Alzheimer’s Disease treatment that originally had high hopes has bitten the dust.  P&G walked away from a partner this week, killing a tiny biotech (stocks covered: PG, ARYX).

And on the front for reviews:

  • Do you remember all the hype and hopes for synthetic blood?  This looks like the last player has gone on to greener pastures.
  • What is a good investment that has backed way off from highs that should show steady growth in the China health care sector?  We evaluated one potential company for this.

These issues are more stock issues than anything else:

Have a happy and safe LONG Fourth of July weekend.  I think there is a new treatment on the market for burnt hand trauma from fireworks, but the FDA has it on hold until next February.

Jon C. Ogg
July 4, 2008

Posted on: July 4, 2008 – 7:31 am in Biotech, Healthcare, Medical, The Week, , , , , , , , , , , , , , , , ,

The Week’s Top BioHealth Issues For Next Week (PFE, TEVA, CRA, IVGN, CMED, ANPI, ISRG, VVUS, CELG)

One key stock to watch next week is Pfizer Inc. (NYSE: PFE). While it has been in the land of the boring forever, watchers are looking to see if it will put in a rival bid over the $4.6 Billion Daiichi Sankyo bid from Japan for a majority stake in India’s number one generic drug maker Ranbaxy.

Speaking of Generics, Teva Pharmaceutical Industries (NASDAQ: TEVA) was weak all week after Mylan Inc. (NYSE: MYL) has signed a pact with India’s NATCO Pharma Ltd. to produce a generic version of Teva’s multiple sclerosis treatment called Copaxone.  As this  was an old favorite buy in generic investor hearts you can imagine this will be covered frequently this next week since the stock is now 15% off of its highs and closer to a 52-week low.

We know that Invitrogen (NASDAQ: IVGN) is buying Applera’s Applied Biosystems (NYSE: ABI) unit.  But what about Celera Group (NYSE: CRA)?  Traders may be looking for the "next merger candidate"and that might fit logically.

China Medical Technologies Inc. (NASDAQ: CMED) went up big on earnings news this last week and continued to rise even by the end of the week further than the initial reaction.  Technicians may have this one on a momentum screen now.

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI) may be of interest after it showed some positive stent data, and its launch of QUILL may all help the perceptions next week on this small molecule company.

It’s always good to know what short sellers are targeting.  The last short selling report showed a huge drop off in the short interest compared to prior reports in large cap biotech stocks like Amgen Inc. (NASDAQ: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), Celgene Corporation (NASDAQ: CELG), and others.  FULL SHORT INTEREST DETAILS HERE.

Intuitive Surgical Inc. (NASDAQ: ISRG) was defended by William Blair this last week and shares managed to rally during the week after that news was out.  After seeing a 3-month low traders may focus here next week as a short bottom fishing attempt.

Vivus Inc. (NASDAQ: VVUS) is hanging tough after a huge gap up in its QNEXA treatment for obesity and for diabetics.  Shares barely closed down on the week, rather impressive for a small cap with a history of not holding gains.  Traders will definitely be keeping their radar eyes on this one for opportunities to buy it up or short it.

Lastly, there was a lot of news on the rheumatoid arthritis front with many companies delivering solid data for drug studies in the debilitating area from companies such as Abbott Laboratories, Array, Eli Lilly, Incyte, J&J, Schering-Plough, and Roche.  Much of the news seems overlooked by the end of a summer week, so watch these for next week.  Solid Developments for Rheumatoid Arthritis (ABT, ARRY, LLY, INCY, JNJ, SGP, RHHBY)

Jon C. Ogg
June 14, 2008

Posted on: June 14, 2008 – 7:31 am in Biotech, Drug companies, The Week, , , , , , , , ,

Top 10 Pre-Market Analyst Calls (ANPI, BP, CBS, JRCC, WFR, SVVS, SNN, SOHU, KNOT, UA)

These are not the only analyst calls affecting shares today, but these are ten of the calls that we are focusing on this Wednesday morning:

  • Angiotech Pharmaceuticals (NASDAQ: ANPI) raised to Outperform at RBC Capital Markets.
  • BP plc (NYSE: BP) raised to Outperform at Credit Suisse.
  • CBS (NYSE: CBS) downgraded to Market Perform at Wachovia; Raised to Hold at Citigroup.
  • James River Coal (NYSE: JRCC) raised to Buy at UBS.
  • MEMC Electronics (NYSE: WFR) downgraded to Neutral at JPMorgan.
  • SAVVIS (NASDAQ: SVVS) downgraded to Hold at Jefferies and downgraded to Equal-Weight at Lehman.
  • Smith & Nephew (NYSE: SNN) raised to Outperform at Wachovia.
  • Sohu.com (NASDAQ: SOHU) downgraded to Perform at Oppenheimer.
  • The Knot, Inc. (NASDAQ: KNOT) raised to Outperform at Oppenheimer.
  • Under Armour (NYSE: UA) downgraded to Hold at Citigroup.

Jon C. Ogg
April 30, 2008

Posted on: April 30, 2008 – 6:36 am in Analyst Calls, , , , , , , , , ,

The 52-Week Low Club

Noah Education (NED) New China IPO, gets pulled down by drop in region’s stocks. Drops to $16.50 from recent high of $23.70.

Moneygram (MGI) Fitch cuts rating. Falls to $17.67 from 52-week high of $35.18.

MGIC Investment (MTG) Analyst puts "underweight" rating on mortgage lender. Down to $20.09 from 52-week high of $70.10.

Angiotech Pharmaceuticals (ANPI) Cuts guidance and get downgrade. Down to $4.18 from 52-week high of $9.67.

Douglas A. McIntyre

Posted on: October 22, 2007 – 4:41 pm in HI/LOW, , , ,

Pre-Market Analyst Calls (October 22, 2007)

AAUK cut to Hold at Citigroup.
ANPI cut to Sector PErform at both RBC & CIBC.
APPB cut to Underperform at Wachovia.
ASH cut to Underperform at Credit Suisse.
AXP cut to Equal Weight at Lehman.
BHP cut to Hold at Citigroup.
CFC cut to Underweight at Lehman.
COF cut to Equal Weight at Lehman.
CTXS raised to Buy at Deutsche Bank.
CLWR raised to Buy at Jefferies.

Read More »

Posted on: October 22, 2007 – 6:54 am in Analyst Calls, , , , , , , , , , , , ,

The 52-Week Low Club: Merrill Lynch (MER)

The list is very long today, so this will have to be confined to the best of the worst.

Radian Group (RDN) Company provides services to mortgage lenders. Not a good business these days. Down to $13.84 from $67.35.

TOUSA (TOA) Home builder. Unsecured creditors have gotten themselves lawyers. Down to $.63 from 52-week high of $11.37.

Journal Communications (JRN) Newspaper company. Down to $8.54 from $14.

Merrill Lynch (MER) Bullish on America? Not today. Big brokerage hits $65.86 down from 52-week high of $98.68.

Angiotech Pharmaceuticals (ANPI) Cuts 2007 revenue outlook. Drops to $4.86 from 52-week high of $9.81.

Movie Gallery (MOVI) In Chapter 11. Drops to $.18 from 52-week high of $5.29.

Douglas A. McIntyre

Posted on: October 19, 2007 – 3:25 pm in HI/LOW, , , , , ,